[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Belousov
Iu B
IuB
Karpov
O I
OI
Belousov
D Iu
DIu
Beketov
A S
AS
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000191:economics / Q000627:therapeutic use; D000863:Antacids / Q000191:economics / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D015738:Famotidine / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D016481:Helicobacter Infections / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006635:Histamine H2 Antagonists / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000191:economics / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D064750:Rabeprazole; D011899:Ranitidine / Q000191:economics / Q000627:therapeutic use; D012426:Russia
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D064750:Rabeprazole; D015738:Famotidine; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole